Esmo 2022 – Lumakras’s lung cancer shocker
Having promised much, Esmo underdelivers with a late-breaker that appears to hand some advantage back to Mirati.
Esmo 2022 – Galleri’s real-world exhibition disappoints
Grail finds the path for its liquid biopsy less clear than it might have hoped.
ISA 2022 – Alnylam takes heart from full Apollo-B data
But it is still unclear how much of a threat Onpattro will be to Pfizer’s Vyndaqel.
Esmo 2022 – Trodelvy’s improving trajectory might not matter much
Later cuts of Tropics-02 make for better reading, but in Her2-driven breast cancer Gilead’s Trodelvy will remain a footnote to Enhertu.
Esmo 2022 – the new liver cancer entrants line up
Late-breakers give tislelizumab, camrelizumab and Keytruda outside chances to add to the first-line armamentarium.
Esmo 2022 – Mirati needs some colorectal cancer urgency
Adagrasib data hold up, but filing timelines are still unclear.
Esmo 2022 – last-minute Kras entry takes centre stage
Amgen’s confirmatory Codebreak-200 trial will feature as a surprising late-breaker at Esmo’s presidential session.
